Braemar Hotels & Resorts Inc
Change company Symbol lookup
Select an option...
BHR Braemar Hotels & Resorts Inc
ESALY Eisai Co Ltd
CNX CNX Resources Corp
WW WW International Inc
IBM International Business Machines Corp
NEP Nextera Energy Partners LP
TMP Tompkins Financial Corp
MFM MFS Municipal Income Trust
HMNKF HMS Networks AB
GPX GP Strategies Corp
Go

Real Estate : Equity Real Estate Investment Trusts (REITs) | Small Cap Value
Company profile

Braemar Hotels & Resorts Inc., formerly Ashford Hospitality Prime, Inc., invests in high revenue per available room (RevPAR), luxury hotels and resorts. The Company conducts its business and owns all of its assets through its operating partnership, Ashford Hospitality Prime Limited Partnership (Ashford Prime OP). The Company operates in the direct hotel investment segment of the hotel lodging industry. As of February 24, 2017, it owned interests in 11 hotel properties in six states, the District of Columbia and St. Thomas, the United States Virgin Islands with 3,702 total rooms, or 3,467 net rooms, excluding those attributable to its joint venture partner. The hotel properties in its portfolio are mainly located in the Unites States urban markets. The Company owns nine of its hotel properties directly, and the remaining two hotel properties through an investment in a majority-owned consolidated entity.

Closing Price
$2.39
Day's Change
-0.04 (-1.65%)
Bid
--
Ask
--
B/A Size
--
Day's High
2.50
Day's Low
2.34
Volume
(Average)
Volume:
264,351

10-day average volume:
279,327
264,351

Fauci predicts U.S. will know if COVID-19 vaccines are effective by "November or December"

10:52 am ET September 23, 2020 (MarketWatch)
Print

Dr. Anthony Fauci, director of National Institute of Allergy and Infectious Diseases, expects to see data from the Phase 3 clinical trials of some COVID-19 vaccine candidates indicating whether the vaccines are safe and effective by "November or December" of this year. Fauci made the remarks while testifying during a congressional hearing on Wednesday. There are four experimental coronavirus vaccines in late-stage studies in the U.S., including candidates developed by AstraZeneca's (AZN.LN) and the University of Oxford, BioNTech (BNTX) and Pfizer Inc. (PFE), Johnson & Johnson (JNJ), and Moderna Inc. (MRNA). "We feel strongly that if we have a combination of adherence to the public health measures together with a vaccine that will be distributed to people in this country and worldwide, we may be able to turn around this terrible pandemic that which we have been experiencing," he said. Drs. Robert Redfield, director for the Centers for Disease Control and Prevention, and Stephen Hahn, commissioner of the Food and Drug Administration, are also testifying.

-Jaimy Lee; 415-439-6400; AskNewswires@dowjones.com

(END) Dow Jones Newswires

September 23, 2020 10:52 ET (14:52 GMT)

Copyright (c) 2020 Dow Jones & Company, Inc.

Earnings Calendar and Events Data provided by |Terms of Use| © 2020 Wall Street Horizon, Inc.

Market data accompanied by is delayed by at least 15 minutes for NASDAQ, NYSE MKT, NYSE, and options. Duration of the delay for other exchanges varies.
Market data and information provided by Morningstar.

Options are not suitable for all investors as the special risks inherent to options trading may expose investors to potentially rapid and substantial losses.
Please read Characteristics and Risks of Standard Options before investing in options.

Information and news provided by ,, , Computrade Systems, Inc., , and

Copyright © 2020. All rights reserved.